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AbstrAct:
In contemporary oncology practice, an urgent need remains to refine the prognostic 
assessment of breast cancer. It is still difficult to identify patients with early 
breast cancer who are likely to benefit from adjuvant chemotherapy. Although 
invasion of cancer cells is the main prognostic denominator in tumor malignancy, 
our molecular understanding and diagnosis are often inadequate to cope with 
this activity. Therefore, deciphering molecular pathways of how tumors invade 
and metastasize may help in the identification of a useful prognostic marker. 
We recently discovered that the secretory small GTPase Rab27B, a regulator of 
vesicle exocytosis, delivers proinvasive signals for increased invasiveness, tumor 
size, and metastasis of various estrogen receptor (ER)-positive breast cancer cell 
lines, both in vitro and in vivo. In human breast cancer specimens, the presence 
of Rab27B protein proved to be associated with a low degree of differentiation 
and the presence of lymph node metastasis in ER-positive breast cancer.
INtrODUctION
Breast cancer remains a top-priority in health care. 
The world-wide number of new cases was estimated 1,15 
million for 2002, only surpassed by lung cancer when 
taking both sexes together. Due to the relatively positive 
prognosis there were 4,4 million survivors up to 5 years 
after diagnosis world-wide. Nevertheless 411 000 annual 
deaths were reported, being the leading cause of cancer 
mortality in women [1]. Estrogen receptor (ER)-positive 
breast cancers, which comprise the majority of breast 
malignancies, carry a better prognosis for disease-free 
survival and overall survival than ER-negative breast 
cancers. However, a significant percentage of women 
with ER-positive breast cancer will die from the disease 
within 10 years [2]. Furthermore, time-dependent tumor 
characteristics currently used in the clinic such as tumor 
size and lymph node status are generally less developed 
in early breast cancer and may be less declarative of risk. 
These examples indicate that more accurate prognostic 
indicators would help in the selection of patients at high 
risk for disease recurrence and death who are candidates 
for systemic adjuvant therapy. Deciphering molecular 
mechanisms of cancer cell invasion, the main prognostic 
denominator in tumor malignancy, may identify useful 
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prognostic markers to cope with this need. We investigated 
a novel pro-invasive pathway, namely the delivery of 
critical factors by Rab GTPases into the tumor ecosystem 
[3].
rAb27b-meDIAteD vesIcle 
trANspOrt regUlAtes breAst 
cANcer cell grOwth AND INvAsION
Vesicular transport is the basic communication 
mechanism between different compartments within a cell 
as well as with the extracellular environment, and consists 
of two membrane trafficking networks: endocytosis and 
exocytosis. Both systems directly impact cell signaling: 
endocytosis regulates the internalization of receptors 
and thereby modulates responses to external stimuli, and 
exocytosis affects signaling by liberating vesicles and 
signaling molecules [4]. Rab GTPases are intracellular 
transport proteins that master vesicle trafficking. The 
activity of the small GTPases is regulated by changes 
in guanine nucleotide binding status. Activated Rabs 
allow vesicles to engage specific effectors required for 
vesicle movement, docking and fusion [5]. Secretory Rab 
GTPases control regulated vesicle exocytosis [6]. After 
cloning the secretory Rab27A and Rab27B genes [7], our 
group has continued to study the cellular function of this 
Rab subfamily [3, 8-10]. The secretory Rab27 subfamily 
consists of the homologues Rab27A and B; they exhibit 
71% identity at the amino acid level. Recently, we 
demonstrated that Rab27B regulates invasive tumor 
growth and metastasis of ER-positive MCF-7, T47D and 
ZR75.1 breast cancer cells using complementary cell 
culture and xenograft mouse models [3]. Overexpression 
of the Rab27B protein to comparable expression levels 
found in poor prognosis primary breast cancer resulted 
in G1 to S phase cell cycle transition, growth and 
invasiveness of cells in cell culture, and invasive tumor 
growth and hemorrhagic ascites production in nude mice. 
Interestingly, we found no such effects with Rab27A in 
vitro and in vivo [3]. Common, but also different non-
redundant functions of Rab27A versus Rab27B have been 
described dependent on the cell type and/or secretory 
process studied [11-14]. Interestingly, Wang et al. (2008) 
reported Rab27A-dependent invasion and xenograft 
metastasis of ER-negative, already invasive, MDA-
MB-231 and MDA-MB-435 breast cancer cells. Rab27A 
mRNA and protein levels increased with the in vitro 
invasive potential of the breast cancer cells studied [15]. 
Figure 1: rab27A and rab27b mrNA and protein expression in mcF-7 and mDA-mb-231 breast cancer cells. 
(A) Rab27A and Rab27B mRNA expression detected via quantitative real-time PCR (relative to human mammary epithelial cell line MCF10A). 
To demonstrate Rab27A and Rab27B mRNA expression we combined 50 ng cDNA, Taqman gene expression master mix reagent and Assays-On-
Demand (Applied Biosystems, Austin, TX) for Rab27B (Assay ID Hs00188156_m1), Rab27A (Assay ID Hs00608302_m1), and the household 
gene PIAA (Assay ID Hs99999904_m1) on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems) using the 2−ΔΔCT method 
for relative gene expression. The cycling conditions comprised 2 min at 50°C, 10 min at 95°C and 40 cycles at 95°C for 15 s and 60°C for 60 s. 
(B) Rab27A and Rab27B protein expression detected via Western blot analysis using the specific goat polyclonal Rab27A antibody (C-20, Santa 
Cruz Biotechnology) and our specific rabbit polyclonal Rab27B antibody. (C) Laser scanning confocal images showing endogenous localization 
of Rab27A and Rab27B (green) and F-actin (red) in MDA-MB-231 and MCF-7 breast cancer cells. Scale bar: 20 µm.
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Using semi-quantitative real-time RT-PCR and primers 
and PCR conditions that were not specified, Wang et al. 
found no Rab27B mRNA expression in non-invasive, 
ER-positive MCF-7 cells, and in invasive ER-negative 
MDA-MB-231 cells [15]. In contrast, we observed both 
Rab27A and Rab27B expression in these cells, employing 
quantitative real-time PCR and Western blotting (Fig. 
1A and B). In fact, the expression levels of Rab27B 
mRNA and protein were higher in ER-positive MCF-
7 cells compared to ER-negative MDA-MB-231 cells; 
Rab27A mRNA and protein levels were higher in ER-
negative MDA-MB-231 cells. In the study of Wang et al. 
Rab27A was found diffusely localized in the cytoplasm, 
with a particular concentration in the perinuclear region 
of MDA-MB-231 and MDA-MB-435 cells. Using laser 
scanning confocal microscopy we revealed a vesicular 
distribution for both Rab27A and Rab27B in MCF-7 
and MDA-MB-231 cells (Fig. 1C). Rab27B exhibits a 
peripheral distribution in MCF-7 cells and a cytoplasmic 
pattern in MDA-MB-231 cells; Rab27A is localized at the 
cell periphery in MDA-MB-231 cells and in the cytoplasm 
in MCF-7 cells. Both we and Wang et al. obtained the cell 
lines directly from ATCC [3, 15]. Differences in Rab27 
expression and localization could be attributed to failure 
of Rab27B-specific primers in the semi-quantitative PCR 
assay or the lack of specificity of the Rab27A antibody 
used by Wang and coworkers. For Western blot analysis, 
we tested three distinct Rab27A antibodies on the cell 
lysates of HEK cells electroporated with previously 
described GFP-Rab27A, GFP-Rab27B or GFP-Rab3A 
constructs [3, 8] (Fig. 2A); One of the Rab27A antibodies 
was non-specific (rabbit polyclonal antibody, Santa 
Cruz Biotechnology). Results in Fig. 1B were obtained 
using the specific goat polyclonal Rab27A antibody (C-
20, Santa Cruz Biotechnology). Specificity of the rabbit 
polyclonal Rab27B antibody has been shown previously 
[3, 11]. Evaluation of the specific goat polyclonal Rab27A 
antibody for laser scanning confocal microscopy was 
performed on primary human melanocytes, a cell type 
with a well studied expression and localization pattern of 
Rab27A [10, 16] (Fig. 2B).
The differences in localization and expression of 
both Rab27 proteins in ER-positive and negative breast 
cancer cell lines could indicate that Rab27A and Rab27B 
play different roles depending on the cells’ ER-status. 
Overexpression of Rab27B in non-invasive ER-positive 
breast cancer cells comparable to levels found in poor-
prognosis primary breast tumors, stimulated invasive 
Figure 2: rab27A antibody testing for western blot analysis and laser 
scanning confocal microscopy. (A) Different Rab27A antibodies were tested for 
Western blot analysis using HEK cells transiently transfected with (1) GFP, (2) GFP-Ra-
b3A, (3) GFP-Rab27A or (4) GFP-Rab27B and (5) are primary melanocytes. Tubulin was 
used as loading control. (B) Laser scanning confocal microscopy of primary melanocytes 
with the specific goat polyclonal Rab27A antibody (C-20, Santa Cruz). Scale bar: 20 µm.
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tumor growth. Rab27B localized to the cell periphery, 
suggesting a secretory function. Since estrogen regulates 
vesicle trafficking gene expression in ER-positive breast 
cancer cells [17], it is of interest to determine Rab27A and 
Rab27B mRNA and protein levels in additional estrogen-
dependent carcinomas such as ovarian carcinoma. Also, 
conflicting reports in the literature suggest that Rab25, 
involved in the recycling of cell surface receptors and 
integrins, could be a context dependent promoter or 
suppressor of tumorigenesis. It has been demonstrated that 
in ER-positive breast cancer cells, Rab25 overexpression 
increases proliferation and anchorage-independent growth 
[18]. In ER-negative breast cancer cells, re-expression of 
Rab25 reduced proliferation and invasive growth, and 
increased apoptosis [19, 20]. 
rAb27b: A prOgNOstIc mArker FOr 
er-pOsItIve breAst cANcer?
Our previous findings indicate that in clinical breast 
cancer samples, up-regulation of endogenous Rab27B, 
but not Rab27A, protein correlates with lymph node 
metastasis and differentiation grade in ER-positive breast 
tumors [3]. In agreement, levels of Rab27B mRNA were 
highest in ER-positive breast cancers with lymph node 
metastasis. Based on this body of evidence, Rab27B 
determines invasiveness and metastasis, and could be 
an important biomarker in the signature of ER-positive 
breast cancers with poor prognosis. The selective presence 
of Rab27B expression in ER-positive tumors might 
suggest Rab27B expression as a confounding factor. By 
definition, a confounding variable is associated with both 
cause and outcome. However, no significant relationship 
was found for the percentage of ER-positivity and lymph 
node status or possible confounder Rab27B. Moreover, 
using percentage ER-positivity, grading, diameter of 
the tumor, and Rab27B score as variables in a logistic 
regression model, only Rab27B score was significantly 
linked to lymph node metastasis (Odds Ratio = 10.1; 95% 
Confidence Interval = 1.67 to 60.93; P = 0.01) (Clinical 
data are available in Supplementary Table 2 in [3]).
cONclUsION
Breast cancer is a heterogeneous disease and its 
biological complexity is a major challenge for translational 
research. In the clinic, additional well-defined biological 
markers could improve breast cancer sub-classification and 
the accuracy of prognostic and therapeutic decisions for a 
tailormade therapy. Use of markers with an affordable and 
widely spread technology, such as immunohistochemistry, 
is of advantage. Rab27B is a potential key marker for 
stratification, prognosis and treatment of early stage ER-
positive breast cancers which are more invasive and tend 
to metastasize more frequently.
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